SYRS stock plummets as late-stage cancer study of lead candidate fails to achieve its primary endpoint leading to the termination of the study.

Renamed newcomer will be positioned between the Sonet and Seltos and go on-sale in early 2025 in India with South African market availability unknown at present.

According to reports, the incident occurred around Thursday midnight. The vehicle, reportedly travelling at high speed, ...

The SELECT-MDS-1 trial showed no significant complete response rate improvement with tamibarotene plus azacitidine for ...

That’s right. Kia has teased the upcoming crossover called the Syros. For now, the Korean manufacturer intends to offer it in ...

A new conviction was issued by the Mixed Jury Court for those responsible for the horrific death of Michalis Paschalakis, ...

Why It Matters: The appointment of Kennedy, a prominent critic of vaccines, as Health Secretary could signal a shift in ...

Merck is playing defense against Summit Therapeutics with a $3.3 billion licensing deal announced Thursday for a cancer drug.

AstraZeneca and Amgen announced that a Phase 3 trial of Tezspire (tezepelumab) showed a statistically significant and ...

At the BioFuture 2024 conference held in New York in November, Seema Kumar, the CEO of Cure, described women’s health as something that has been directed at the “bikini area.” That “bikini” bias ...

Even more impressive is the fact the JS8 PHEV can travel up to 84 km on pure electric power based on the WLTC cycle. With a ...